Publications by authors named "Cece Kpamou"
Background: We aimed to estimate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence among the general population in Conakry, Guinea and Yaounde, Cameroon after the coronavirus disease 2019 Omicron wave.
Methods: We conducted population-based, age-stratified seroprevalence surveys in Conakry and Yaounde (May and June 2022). We collected demographic and epidemiologic information and dried blood spot samples that were tested for SARS-CoV-2 immunoglobulin G (IgG) antibodies using recombinant nucleocapsid and spike proteins with Luminex technology.
Background: Insufficient long-term data are available on antibody kinetics in survivors of Ebola virus disease (EVD). Likewise, few studies, with very small sample sizes, have investigated cross-reactions between Ebolavirus spp. In this study, we aimed to assess the humoral antibody response and its determinants in survivors of EVD and assess cross-reactivity of antibodies between diverse Ebolavirus spp.
View Article and Find Full Text PDFArticle Synopsis
- Three seroprevalence surveys were conducted in Conakry, Guinea, over a period of 6 months to assess COVID-19 spread using cluster sampling.* -
- Seroprevalence rates rose significantly from 17.3% in December 2020 to 42.4% by June 2021, indicating persistent transmission across all age groups.* -
- These findings could help shape effective public health response strategies to manage the epidemic in the community.*
Background: Longitudinal analyses are needed to better understand long-term Ebola virus disease (EVD) sequelae. We aimed to estimate the prevalence, incidence, and duration of sequelae and to identify risk factors associated with symptom occurrence among EVD survivors in Guinea.
Methods: We followed 802 EVD survivors over 48 months and recorded clinical symptoms with their start/end dates.
A 40-Month Follow-Up of Ebola Virus Disease Survivors in Guinea (PostEbogui) Reveals Long-Term Detection of Ebola Viral Ribonucleic Acid in Semen and Breast Milk.
Open Forum Infect Dis
December 2019
Background: With the increasing frequency and impact of Ebola virus disease (EVD) outbreaks illustrated by recent epidemics, a good understanding of the extent of viral persistance or ribonucleic acid (RNA) detection in body fluids from survivors is urgently needed.
Methods: Ebola viral RNA shedding was studied with molecular assays in semen (n = 1368), urine (n = 1875), cervicovaginal fluid (n = 549), saliva (n = 900), breast milk (n = 168), and feces (n = 558) from EVD survivors in Guinea (PostEbogui cohort, n = 802) at a regular base period until 40 months after inclusion.
Results: Twenty-seven of 277 (9.
Prevalence of infection among asymptomatic and paucisymptomatic contact persons exposed to Ebola virus in Guinea: a retrospective, cross-sectional observational study.
Lancet Infect Dis
March 2019
Article Synopsis
- The study aimed to assess the prevalence and risk factors related to Ebola virus infection among unvaccinated individuals who had contact with Ebola patients in Guinea between 2016 and 2017.
- Researchers interviewed 1,721 contact persons, excluding 331 vaccinated individuals, resulting in a study group of 1,390, where 216 participants reported symptoms.
- The findings revealed seropositivity rates of 8.33% among symptomatic individuals and 3.32% among asymptomatic ones, with increased risk linked to participation in burial rituals and exposure to bodily fluids.
Background: The high number of survivors from the 2013-16 west African outbreak of Ebola virus disease (EVD) has raised several new issues: long-term clinical complications, psychosocial consequences, risks of EVD reactivation, and secondary transmission due to viral persistence in body fluids. We aimed to assess long-term clinical, psychosocial, and viral outcomes in EVD survivors in Guinea.
Methods: In this multidisciplinary observational cohort study, we recruited patients aged 1 year or more in four sites in Guinea (Donka National Hospital, Conakry; Macenta Prefectoral Hospital, Macenta; N'zérékoré Regional Hospital, N'zérékoré; and Forécariah Prefectoral Hospital, Forécariah) following discharge from any Ebola treatment centre in Guinea.